31 October 2023 - - The MSAC Secretariat has published a revised ist of applications scheduled to be considered by the MSAC on 23 -24 November 2023.

The agenda now has 11 items. Applications of note include:

• 1690.1 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma
• 1716 – Germline BRCA mutation test to detect BRCA1 or BRCA2 mutations in patients with HER2- negative high risk early breast cancer to determine eligibility for PBS-listed olaparib treatment
• 1723.1 - Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia
• 1758 - Expansion of MBS item numbers 12320 & 12322 for bone mineral density testing to include patients aged 60-69 years (withdrawn)

Read MSAC agenda